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Abstract
Background: Glycosphingolipids are important compounds of the plasma membrane of mammalian cells and
a number of them have been associated with malignant transformation and progression, reinforcing tumour
aggressiveness and metastasis. Here we investigated the levels of naturally occurring anti-glycan antibodies to
Globo H in blood plasma obtained from high-grade serous ovarian cancer patients (SOC) and women without
gynaecological malignancies (control) using suspension glycan array technology employing chemically synthesized
glycans as antibody targets.
Results: We found that anti-human Globo H IgG antibodies were able to significantly discriminate SOC from
controls (P < 0.05). A combination with the clinically used tumour marker CA125 increased the diagnostic
performance (AUC 0.8711). We next compared suspension array with standard flow cytometry in plasma samples
and found that the level of anti-Globo H antibodies highly correlated (r = 0.992). The incubation of plasma-derived
anti-glycan antibodies with chemically synthesized (presented on fluorescence microspheres) and native Globo H
(expressed on Globo H-positive cell lines) revealed strong reactivity of naturally occurring human anti-Globo H
antibodies towards its antigen expressed on ovarian cancer cells.
Conclusions: Our data demonstrate that human plasma-derived antibodies to Globo H as well as the presence of
the antigen might be considered as therapeutic option in ovarian cancer.
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Background
Globo H is a glycosphingolipid of the globo series with a
sugar terminus resembling the blood group antigen H
determinant. First identified in human teratocarcinoma
and breast cancer cells [1, 2], Globo H was found to be
overexpressed on the cell surface of several epithelial
cancers such as breast, colon, endometrial, gastric,
pancreatic, lung, and prostate cancers [3–5]. It is also
moderately expressed in normal epithelial tissues (lung,
breast, prostate, stomach, pancreas, and ovary), but its
distribution is restricted to apical epithelial cells at
lumen borders [5]. Functionally, Globo H has been
associated with tumour stem cells [6], to be a potent
inducer of angiogenesis [7], and an immunosuppressor
through Notch signalling [8]. The high Globo H
expression by only cancer and cancer stem cells made it
an attractive target for generation of therapeutic cancer
vaccines. These vaccines underwent the long history of
development and improvement and are currently being
tested in clinical trials for treatment [9–11]. Globo H
has therefore been considered as one promising tumor-
associated glycan biomarker, in particular for breast
cancer.
Plasma-derived naturally occurring anti-glycan anti-
bodies (AGA) have been associated to various human
diseases including cystic fibrosis [12], Crohn’s disease
[13], and various malignancies [14–18]. Also healthy
humans harbour sets of AGA to blood group-, xeno-
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(heterophil), and infection-related glycan motifs [19].
Globo H was also shown to be an antigen for natur-
ally occurring plasma-derived AGA in breast and
some other epithelial cancers with high specificity
[20]. These antibodies were assessed by the glycan
microarray technology and their levels were signifi-
cantly different in serum of breast cancer patients
and healthy individuals [21]. Despite these few re-
ports, there is limited knowledge on Globo H antigen
expression on cell lines and the presence of naturally
circulating AGA in plasma from ovarian cancer
patients.
We assessed the levels of anti-Globo H antibodies of
IgG and IgM isotypes in healthy and serous ovarian
cancer (SOC) patients. We used our “in house” devel-
oped suspension glycan array (SGA), a robust tool for
AGA profiling [15, 22], to detect anti-Globo H anti-
bodies in human plasma samples for discrimination of
ovarian cancer patients and normal controls. We also
compared SGA and standard flow cytometry in order to
address the following questions; a) whether AGA levels
are comparable in both methods, and b) whether those
antibodies can recognize native Globo H epitope on the
cell surface of cancer cell lines.
Methods
Human subjects
Two groups of female donors were involved in the current
study. All patients were over the age of 18 and were
prospectively included after giving informed consent in
accordance with ethical regulations (Hunter Area Re-
search Ethics 04/04/07/3.04; South Eastern Sydney
Illawarra HREC/AURED Ref:08/09/17/3.02). The serous
ovarian cancer (SOC) group consisted from patients with
serous ovarian cancer with Grade 2 and 3 of all FIGO
stages (SOC n = 19). The control group (n = 29) consisted
of women without macroscopically confirmed gynaeco-
logical malignancy including comprising of benign donors,
patients with benign gynaecological tumours (leiomyoma,
cystadenoma, or fibroadenoma) and patients undergoing
medical control due to previous family history of breast
cancer or bearing known BRCA mutations. Women in the
control group had no other type of malignancy at the date
of collection. Patients were either admitted with an
adnexal mass to the Gynaecological Cancer Centre of the
Royal Hospital for Women, Randwick, Australia or were
seen as outpatients to the Hereditary Cancer Centre of
The Prince of Wales Hospital, Randwick, Australia. The
processing of blood plasma samples was performed as
previously described [15, 23].
Suspension glycan array
Glyco-polymers with end-biotin group- Sialylated and
sulfated glycans were chemically synthesised (Lectinity
Holdings, Moscow, Russia. The glycopolymers, Glyc(20)–
PAA–biot1, used for coupling to fluorescent beads were
produced in-house as previously described [24]. The
glycopolymers are composed of a polyacrylamide carrier
(PAA, number of the average polymerisation degree, n =
220) provided with end biotin groups and side-pendant Glyc
residues, that are statistically distributed along the polymer
backbone. The content of monomer units with glycan
substitution is 20 mol %. Non-glycosylated monomer units
are substituted with an ethanolamine residue for the regular
Glyc(20)–PAA–biot1. GD3 and GM2 glycans were pur-
chased from Elicityl (Crolles, France) and then used for
synthesis of Glyc(20)–PAA–biot1, as described above.
Modification of fluorescent microbeads- Biotinylated
glycopolymers were coupled to fluorescent Bio-Plex
Pro™ Magnetic COOH beads of 6.5 μm diameter with
distinct spectral “addresses” (Bio-Rad Laboratories Inc.,
Cressier, Switzerland). Each bead’s region was embedded
with a precise ratio of red and infrared fluorescent dyes
allowing its identification using Bio-Plex 200 Suspension
Array System (Bio-Rad Laboratories Inc., Hercules, CA,
USA). Coupling of biotinylated glycopolymers using biot–
PEG23–NH2 (Hetero-bifunctional PEG, MW= 1300, Iris
Biotech GmbH, Marktredwitz, Germany) modification of
microbeads was accomplished as described previously
[25]. All remaining steps were performed as described
previously [25]. Data are presented as median MFI and
interquartile range (IQR).
ELISA
CA125 levels in blood samples obtained from patients
were measured using the human CA125 ELISA kit
(MUC16) SimpleStep (Abcam, LucernaChem AG,
Switzerland, #ab195213). ELISA was performed according
to manufacture’s protocol.
Cell culture
Ovarian (IGROV1, A2780, SKOV3, BG1, OVCAR3,
OVCAR4, OVCAR5, OVCAR8, OAW42, TYK-nu, KUR-
AMUCHI, OVSAHO, CAOV3, and TOV21G), and breast
(T47D and MCF7) cancer cell lines, ovarian surface
epithelial cells (HOSE17.1 and HOSE6.3) and normal
mammary epithelial cell line MCF10A were grown in
RPMI-1640 media (Sigma-Aldrich, Buchs, Switzerland)
supplemented with 10% fetal bovine serum (FBS), penicil-
lin (100U/ml) and streptomycin (100 μg/ml) (obtained
from Sigma-Aldrich). Fallopian tube secretory epithelial
cells (FT237 and FT240) were grown in DMEM-Ham’s
F12 medium without HEPES buffer (Sigma) supple-
mented with UltroserTm (PALL corporation, Life Science,
Switzerland), penicillin (100U/ml) and streptomycin
(100 μg/ml). Another ovarian cancer cell line, EFO27 were
grown in RPMI-1640 media supplemented with 20% FBS,
penicillin (100U/ml), streptomycin (100 μg/ml) and 1 mM
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sodium pyruvate (purchased from Sigma). The culture
condition for all cell lines were 37 °C in a 95% humidified
atmosphere containing 5% CO2.
Flow cytometry
Cells were seeded in T25cm2 flask cultivated to 70–80%
confluence, washed with PBS, harvested with 1x non-
enzymatic cell dissociation solution at 37 °C and counted
using trypan blue. Cells were than transferred to 96-
well- V-bottom micro test plate (105 cells/well) and pel-
letized at 400xg for 5 min. Analysis of cell membrane–
bound Globo H was performed with two-step staining
procedure. Anti-Globo H antibodies (Mbr1_IgM_1:500,
diluted in FACSWASH (1% BSA in PBS)) were added to
cells, resuspended and incubated on ice for 1 h. After
two washes with FACSWASH, cells were incubated with
R-PE (1:200) on ice for 30 min. Following two washing
steps, cells were incubated with 7-AAD (1:100) on ice
for 10 min. After the final wash, cells were resuspended in
200 μl of FACSWASH and analyzed with BD Accuri C6
flow cytometer (BD Pharmingen). Analysis of inhibition
experiments using microspheres and human cell lines
were analyzed with BD LSR Fortessa. Data analysis was
done using FlowJo v10.0.4 (Tree Star Inc., Ashland, USA).
Statistical analysis
The raw data (obtained as MFI) were log-transformed.
Statistical analysis was either performed by GraphPad
Prism 6 software or the statistical software R version
3.1.3 (www.R-project.org). Penalized logistic regression
and receiver operating characteristics (ROC) analysis was
performed using the R packages ‘glmnet’ and ‘ROCR’ [26],
respectively. Comparisons between subgroups were per-
formed using Mann Whitney U-test. A p value < 0.05 was
considered significant.
Results and discussion
Studies in the past suggested that levels of anti-Globo H
antibodies are predictive for breast cancer [20, 21].
Recent genomic and transcriptomic analyses by the
Cancer Genome Atlas (TCGA) revealed that basal-like
breast cancer displays significant molecular similarities
to undifferentiated (high-grade) SOC [27, 28]: both
diseases share molecular signatures (e.g. mutations in
TP53, BRCA1/2, and RB1). Thus, we investigated the
presence of AGA to Globo H in a cohort of 48 blood
plasma samples, consisting of high-grade SOC (n = 19)
and a control group (n = 29) comprising women with-
out or benign disease of the gynaecological tract (e.g.
leiomyoma, cystadenoma, or fibroadenoma).
The SGA utilized to measure AGA [22, 25] incorpo-
rated coupling of microspheres with an internal fluores-
cence to chemically synthesized glycans (Fig. 1a) via a
linker (Fig. 1b). Using monoplexed SGA levels of
antibodies to alpha-rhamnose (positive control) and
Globo H were generally high for both isotypes in all
samples (Fig. 1c-e). In contrast, aminoglucitol (negative
control) showed AGA levels below the threshold
(Fig. 1c). We observed significantly decreased anti-globo
H antibody levels of IgG isotype in SOC patients to the
control group (IgG 2642 MFI (338; 6067), p = 0.009,
Fig. 1d-e), hence clearly discriminating cancer patients
from healthy controls. The comparison for the IgM iso-
type showed a similar trend (1526 (492; 4154), p = 0.071,
Fig. 1d-e). We next performed ROC analysis including
the current clinical ovarian cancer biomarker CA125,
which was measured by ELISA during clinical exami-
nations at initial diagnosis. The combination of anti-
Globo H IgG and IgM revealed an area under the
curve (AUC) of 0.7441. The addition of CA125 in a
penalized logistic regression model increased the AUC
to 0.8711, which was even higher than CA125 alone
(AUC 0.8539). This indicates that anti-globo H anti-
body levels improve the diagnostic performance of
CA125 alone (Fig. 1f ).
Despite this intriguing finding it remained to be eluci-
dated whether anti-Globo H antibodies are capable to
bind the native Globo H antigen expressed on ovarian
cancer cells and whether plasma-derived AGA also
recognize other glycan structures (epitopes similar to
Globo H). Thus, we profiled a panel of ovarian (n = 15)
and breast (n = 2, used as positive control, [11]) cancer
cells (Fig. 2a) using the monoclonal antibody MBr1
(Fig. 2a). After the evaluation of the MBr1 in breast
cancer cell lines MCF7 and T47D, the working concen-
tration 2.5 μg/ml MBr1 was selected. We observed
Globo H expression in only three ovarian cancer cell
lines, OVCAR3, BG1, and IGROV1 (Fig. 2a). The
remaining ovarian cancer cell lines never showed any
positivity for Globo H. The normal ovarian surface
epithelial cell lines (HOSE17-1 and HOSE6-3), fallopian
tube secretory epithelial cells (FT237 and FT240), and
the mammary epithelial cell line MCF10A were also
negative for Globo H (Fig. 2a). In contrast to our
findings, the literature reported Globo H expression
also in TOV21G ovarian cancer cells [29]. This dis-
crepancy might be explained by the use of different
monoclonal antibodies to Globo H (MBr1 and VK9)
in these two studies.
In order to study the binding of naturally occurring
anti- Globo H antibodies from patient samples to
Globo H-positive ovarian cancer cell lines, we com-
pared SGA and standard flow cytometry. A total of
fourteen plasma samples reflecting the spectrum of
antibody levels were selected and profiled using both
methods. The comparison revealed a high correlation
(r = 0.992, p < 0.0001) concluding that flow cytometry is
suitable for AGA profiling (Fig. 2b).
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Fig. 1 Plasma-derived anti-glycan antibodies of IgG and IgM isotype bind to polymeric presented Globo H glyco-clusters differentiating healthy
controls from ovarian cancer comparable to CA125. a Schematic presentation of the coupling procedure of end-biotinylated glycoconjugates to
streptavidin containing beads. b Chemical structure of Globo H conjugated to biotin. c Human AGA (log median fluorescence intensity for IgG
and IgM separately) binding to positive (alpha-rhamnose) and negative (aminoglucitol) control. (d & e) Box-and-whisker plot showing distribution
of AGA levels directed to Globo H in the blood plasma of serous ovarian cancer (SOC) patients and control group. f ROC curve for both antibody
classes (IgG and IgM) together and with CA125 together. Individual CA125 levels are displayed
Fig. 2 Anti-Globo H antibodies bind ovarian cancer cell lines determined to express naturally synthesized Globo H on the cell surface membrane.
a Flow cytometry results showing expression of Globo H in selected breast and ovarian cancer cell lines. Representative histograms for cell lines
HOSE17.1, FT237, OVCAR3, BG1, MCF10A and MCF7. The percentages of positively stained cells were displayed and are a representative of five
independent experiments. Bar chart summarizing five independent experiments on all cell lines tested showing the mean and standard deviation for
each cell line. b SGA and FACS show high correlation for binding of plasma-derived anti-Globo H antibodies to Globo H-coupled microbeads (SGA)
and Globo-H positive cells (FACS, here MCF7 cells); plasma samples 1–14, dilutions 1/40 (SGA) and 1/200 (FACS). MFI values were log-transformed. c
Flow cytometry data represented as histogram for negative control (light grey) and positively stained sample (dark grey). The value provided in each
histogram refers to the percentage of positively stained cells
Pochechueva et al. Journal of Ovarian Research  (2017) 10:8 Page 4 of 6
To finally prove that plasma antibodies indeed bind to
Globo H on the cell surface, we co-incubated anti-Globo
H positive plasma (a pool of five individual samples)
with Globo H-coupled microbeads (105 beads). As a
negative control we used MCF10A. We found that
plasma antibody binding decreased to different extents
among all Globo H positive cancer cell lines (MCF7,
T47D, and OVCAR3) tested in flow cytometry (Fig. 2c).
We did not achieve pronounced decrease of binding
using plasma dilution 1/5–1/100 as well as with combin-
ation of less than 0.5 × 105 beads. The plasma binding in
case of MCF10A was high (86%) and did not decrease
after plasma pre-incubation with Globo H beads (Fig. 2c).
These data clearly demonstrate that ovarian cancer cells
express Globo H and that the antigen is recognized by
naturally occurring anti-Globo H antibodies from human
blood plasma.
Taken together, we demonstrate that women with
SOC and benign disease display different levels of
anti-Globo H antibodies. Moreover, these antibodies
are capable to bind Globo H expressing ovarian
cancer cell lines.
Conclusions
In this study we report on naturally occurring AGA to a
well-known tumour-associated carbohydrate antigen
(Globo H) in ovarian cancer. The current study is based
on Globo H identified by circulating AGA as well as the
monoclonal antibody MBr1. However, future studies
have to consider larger cohorts and the measurement of
combinations with other representative biomarkers in-
cluding AGA to evaluate the diagnostic performance of
Globo H. Further studies might also incorporate mass
spectrometry to confirm the presence of the antigen in
ovarian cancer cells. Verification in tissue samples might
also support a potential role of Globo H in this malignant
disease, e.g. by MALDI imaging mass spectrometry [30].
This knowledge might also contribute to our understanding
of the functional role of Globo H as it has been associated
with cancer stem (−like) cells previously [31].
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